Literature DB >> 3304969

Infective endocarditis. Current recommendations for prophylaxis.

S Lang, A Morris.   

Abstract

Antibiotic prophylaxis is indicated for any patient with a predisposing cardiac lesion who undergoes a procedure likely to produce bacteraemia with an organism having the propensity to cause bacterial endocarditis. Cardiac abnormalities have been ranked according to their approximate risk and it is known that the organisms most likely to cause endocarditis are viridans streptococci, Group D streptococci and staphylococci. The procedures likely to induce bacteraemia with each of these are, respectively, dental and upper respiratory with bleeding, urinary and gastrointestinal, and cardiac valve surgery. Antibiotic prophylaxis is impractical when bacteraemia cannot be anticipated and is unnecessary when it is due to organisms such as anaerobes and Gram-negative bacilli which rarely colonise the endocardium. A variety of prophylactic antibiotic regimens, directed against the common aetiological organisms, have been evaluated in animal models of infective endocarditis and it is on the basis of this kind of indirect evidence that several expert committees have made and regularly update their recommendations. Because infective endocarditis is an uncommon disease, a controlled clinical trial to prove the efficacy of prophylaxis would require the enrolment of a prohibitive number of patients. Consequently, there is room for differences of opinion over what constitutes optimum prophylaxis in any particular situation. This review examines the rationale for prophylaxis and compares and contrasts several authoritative recommendations, among which the trend in recent years has been towards simpler oral regimens.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3304969     DOI: 10.2165/00003495-198734020-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  12 in total

1.  Prevention of infective endocarditis associated with dental treatment and other medical intervention.

Authors:  D R Hay; R B Ellis-Pegler; J Faoagali; P N Leslie; J M Neutze
Journal:  N Z Med J       Date:  1985-12-11

2.  Prevention of bacterial endocarditis.

Authors: 
Journal:  Med Lett Drugs Ther       Date:  1986-02-14       Impact factor: 1.909

3.  Prophylaxis of endocarditis. Comparison of the new regimens.

Authors:  B F Farber
Journal:  Am J Med       Date:  1987-03       Impact factor: 4.965

4.  The antibiotic prophylaxis of infective endocarditis. Report of a working party of the British Society for Antimicrobial Chemotherapy.

Authors: 
Journal:  Lancet       Date:  1982-12-11       Impact factor: 79.321

5.  Therapeutics Advisory Committee. Prevention of infective endocarditis associated with dental treatment and dental disease. Report of the Committee.

Authors: 
Journal:  Aust Dent J       Date:  1980-02       Impact factor: 2.291

6.  Current issues in prevention of infective endocarditis.

Authors:  D T Durack
Journal:  Am J Med       Date:  1985-06-28       Impact factor: 4.965

7.  Prevention of Bacterial Endocarditis. A statement for health professionals by the Committee on Rheumatic Fever and Infective Endocarditis of the Council on Cardiovascular Disease in the Young.

Authors:  S T Shulman; D P Amren; A L Bisno; A S Dajani; D T Durack; M A Gerber; E L Kaplan; H D Millard; W E Sanders; R H Schwartz
Journal:  Circulation       Date:  1984-12       Impact factor: 29.690

8.  Transient bacteremia and endocarditis prophylaxis. A review.

Authors:  E D Everett; J V Hirschmann
Journal:  Medicine (Baltimore)       Date:  1977-01       Impact factor: 1.889

9.  The bowel, the genitourinary tract, and infective endocarditis.

Authors:  R Bayliss; C Clarke; C M Oakley; W Somerville; A G Whitfield; S E Young
Journal:  Br Heart J       Date:  1984-03

10.  Successful prophylaxis of experimental streptococcal endocarditis with single doses of sublethal concentrations of penicillin.

Authors:  P Francioli; M P Glauser
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.